Pediatrics Doctors in Hastings, MN Accepting Medicare

4 Pediatrics doctors found. Showing 1 - 4

Sanaya Darayus Bharucha, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1285 Nininger Rd, Hastings, MN 55033 Phone: 651-480-4200

Dr. Janene R Glyn, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1285 Nininger Rd, Hastings, MN 55033 Phone: 651-480-4200

Dr. Nicholas Venosdel, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1210 1st St W, Hastings, MN 55033 Phone: 651-438-1800

Dr. Maria O Stanislaw, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 1285 Nininger Rd, Hastings, MN 55033 Phone: 651-480-4200

News Archive

Leukemia relapse stems from DNA repair function loss

A University of Kentucky research team reports that loss of an important DNA repair function, called DNA mismatch repair (MMR), is responsible for refractory/relapsed Acute Myeloid Leukemia (AML).

Highly sensitive blood test may help doctors tailor better breast cancer treatments

A new, highly sensitive blood test is one of the first to successfully monitor breast cancer patients with early stage disease and could be up to 100 times more sensitive than existing tests, according to a study published in Science Translational Medicine today (Wednesday).

Intendis granted rights to KYTHERA's ATX-101 candidate for minimally-invasive fat reduction outside US, Canada

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

U.S. District Court grants Cephalon Temporary Restraining Order for generic AMRIX

Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc., and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon's branded product AMRIX.

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Synta Pharmaceuticals Corp. - Ganetespib, a potent, second generation Hsp90 inhibitor, has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer according to Phase 2 clinical trial results presented by researchers from Memorial Sloan-Kettering Cancer Center at the San Antonio Breast Cancer Symposium.

Read more Medical News

› Verified 7 days ago